Somatic Genome-Engineered Mouse Models Using In Vivo Microinjection and Electroporation

被引:0
|
作者
Harwalkar, Keerthana [1 ,2 ]
Yamanaka, Nobuko [1 ,3 ]
Yamanaka, Yojiro [1 ,2 ,3 ]
机构
[1] McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ, Canada
[2] McGill Univ, Dept Human Genet, Montreal, PQ, Canada
[3] McGill Univ, McGill Integrated Core Anim Modeling MICAM, Montreal, PQ, Canada
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2023年 / 195期
关键词
CANCER; HETEROGENEITY; EPITHELIUM; CARCINOMA; ROLES;
D O I
10.3791/65131
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Germline genetically engineered mouse models (G-GEMMs) have provided valuable insight into in vivo gene function in development, homeostasis, and disease. However, the time and cost associated with colony creation and maintenance are high. Recent advances in CRISPR-mediated genome editing have allowed the generation of somatic GEMMs (S-GEMMs) by directly targeting the cell/tissue/organ of interest. The oviduct, or fallopian tube in humans, is considered the tissue-of-origin of the most common ovarian cancer, high-grade serous ovarian carcinomas (HGSCs). HGSCs initiate in the region of the fallopian tube distal to the uterus, located adjacent to the ovary, but not the proximal fallopian tube. However, traditional mouse models of HGSC target the entire oviduct, and thus do not recapitulate the human condition. We present a method of DNA, RNA, or ribonucleoprotein (RNP) solution microinjection into the oviduct lumen and in vivo electroporation to target mucosal epithelial cells in restricted regions along the oviduct. There are several advantages of this method for cancer modeling, such as 1) high adaptability in targeting the area/tissue/organ and region of electroporation, 2) high flexibility in targeted cell types (cellular pliancy) when used in combination with specific promoters for Cas9 expression, 3) high flexibility in the number of electroporated cells (relatively low frequency), 4) no specific mouse line is required (immunocompetent disease modeling), 5) high flexibility in gene mutation combination, and 6) possibility of tracking electroporated cells when used in combination with a Cre reporter line. Thus, this cost-effective method recapitulates human cancer initiation.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] ADAPTING ENGINEERED CELL THERAPIES TO UNDERSTAND AND OVERCOME GLIOBLASTOMA RESISTANCE USING INTEGRATED IN VIVO AND EX VIVO MODELS
    Satterlee, Andrew
    Dunn, Denise
    Floyd, Scott
    Hingtgen, Shawn
    NEURO-ONCOLOGY, 2019, 21 : 275 - 275
  • [32] Transient expression analysis of the mouse ornithine decarboxylase antizyme haploid-specific promoter using in vivo electroporation
    Ike, A
    Ohta, H
    Onishi, M
    Iguchi, N
    Nishimune, Y
    Nozaki, M
    FEBS LETTERS, 2004, 559 (1-3): : 159 - 164
  • [33] Many ways to telomere dysfunction:: in vivo studies using mouse models
    Goytisolo, FA
    Blasco, MA
    ONCOGENE, 2002, 21 (04) : 584 - 591
  • [34] Long-term in vivo gene expression in mouse kidney using φC31 integrase and electroporation
    Otani, Yuki
    Kawakami, Shigeru
    Mukai, Hidefumi
    Fuchigami, Yuki
    Yamashita, Fumiyoshi
    Hashida, Mitsuru
    JOURNAL OF DRUG TARGETING, 2015, 23 (05) : 427 - 435
  • [35] DNA Immunization Using in vivo Electroporation for Generating Monoclonal Antibodies Against Mouse IL-9R
    Takatsuka, Shogo
    Yamada, Hiroyuki
    Haniuda, Kei
    Ichihashi, Marina
    Chiba, Joe
    Kitamura, Daisuke
    BIO-PROTOCOL, 2019, 9 (04):
  • [36] In vivo quantitative bioluminescence tomography using heterogeneous and homogeneous mouse models
    Liu, Junting
    Wang, Yabin
    Qu, Xiaochao
    Li, Xiangsi
    Ma, Xiaopeng
    Han, Runqiang
    Hu, Zhenhua
    Chen, Xueli
    Sun, Dongdong
    Zhang, Rongqing
    Chen, Duofang
    Chen, Dan
    Chen, Xiaoyuan
    Liang, Jimin
    Cao, Feng
    Tian, Jie
    OPTICS EXPRESS, 2010, 18 (12): : 13102 - 13113
  • [37] Many ways to telomere dysfunction: in vivo studies using mouse models
    Fermín A Goytisolo
    María A Blasco
    Oncogene, 2002, 21 : 584 - 591
  • [38] Preclinical testing using tumors from genetically engineered mouse mammary models.
    Varticovski, L.
    Hollingshead, M. G.
    Anver, M. R.
    Robles, A. I.
    Green, J. E.
    Hunter, K. W.
    Merlino, G.
    Nunez, N.
    Hursting, S. D.
    Steeg, P. S.
    Barrett, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 557S - 557S
  • [39] Using genetically engineered mouse models of cancer to aid drug development: An industry perspective
    Singh, Mallika
    Johnson, Leisa
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5312 - 5328
  • [40] Understanding DCIS initiation and progression using PDX and genetically engineered mouse and rat models
    Hutten, Stefan
    Lutz, Catrin
    Scheele, Colinda
    Badoux, Madelon
    Eijkman, Timo
    Annunziatio, Stefano
    Wesseling, Jelle
    Jonkers, Jos
    CANCER RESEARCH, 2020, 80 (11) : 72 - 72